Thanks Linda! I hadn't had a chance to post this info yet, I've been doing 12 hour shifts and trying to fix my stupid laptop...
Biogen and Elan were approved for a label change for Tysabri.
"The included data shows the risk of getting the infection is 0.3 patients per 1,000 when using the drug for less than two years. That rate rises when using the drug for two to three years, to 1.5 cases, but notably drops to 0.9 cases for the period of three to four years. The data is current as of January and Biogen said the label will be updated as needed."
http://online.wsj.com/article/BT-CO-...07-712561.html
The article linked to also addresses the test for antibodies and the plan to add it to the label.